Association Between Atherogenic Index of Plasma and Type 2 Diabetic Complications: a Cross-sectional Study

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2025 Feb 19

PMID 39968299

Authors

Yue-Yang Zhang

Xiao-Yu Yang

Qin Wan

Affiliations

Soon will be listed here.

Abstract

Background: The Atherogenic Index of Plasma (AIP) was originally developed primarily as a marker for assessing atherosclerosis. Consequently, this study investigates the potential association between AIP and type 2 diabetic complications through a cross-sectional design.

Methods: The National Metabolic Management Center(MMC) serves as a comprehensive platform dedicated to the establishment of standardized protocols for the diagnosis, treatment, and long-term follow-up of metabolic diseases. Following the relevant inclusion and exclusion criteria, a total of 3,094 patients were enrolled for subsequent analysis. In this study, logistic regression, restricted cubic splines, and subgroup analyses were employed to evaluate the association between the AIP and four major complications of type 2 diabetes, namely, type 2 diabetes with carotid atherosclerosis (DA), diabetic kidney disease (DKD), diabetic retinopathy (DR), and diabetic peripheral neuropathy (DPN).

Results: The logistic regression results demonstrate that in the fully adjusted model, each SD increase in AIP correlates with an elevated risk of type 2 diabetic kidney disease (DKD), with the risk of kidney damage intensifying alongside higher AIP groupings. The RCS analysis and subgroup analyses similarly revealed a dose-response relationship between AIP levels and the risk of DKD. Furthermore, the AIP was not found to be statistically significantly associated with DA, DR,and DPN.

Conclusions: The AIP may serve as a valuable predictive indicator for evaluating kidney damage in patients with type 2 diabetes, and regular screening of AIP in this population could provide significant benefits in the prevention of DKD.

References

Vujosevic S, Aldington S, Silva P, Hernandez C, Scanlon P, Peto T . Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes Endocrinol. 2020; 8(4):337-347. DOI: 10.1016/S2213-8587(19)30411-5. View

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

Dobiasova M, Frohlich J . The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001; 34(7):583-8. DOI: 10.1016/s0009-9120(01)00263-6. View

Yan Y, Wu T, Zhang M, Li C, Liu Q, Li F . Prevalence, awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population. BMC Public Health. 2022; 22(1):1382. PMC: 9295461. DOI: 10.1186/s12889-022-13759-9. View

Artasensi A, Pedretti A, Vistoli G, Fumagalli L . Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules. 2020; 25(8). PMC: 7221535. DOI: 10.3390/molecules25081987. View

Chen L, Magliano D, Zimmet P . The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives. Nat Rev Endocrinol. 2011; 8(4):228-36. DOI: 10.1038/nrendo.2011.183. View

. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2023; 47(Suppl 1):S20-S42. PMC: 10725812. DOI: 10.2337/dc24-S002. View

Li H, Miao X, Zhong J, Zhu Z . Atherogenic Index of Plasma as an Early Marker of Chronic Kidney Disease and Liver Injury in Type 2 Diabetes. Clin Med Insights Endocrinol Diabetes. 2024; 17:11795514241259741. PMC: 11163926. DOI: 10.1177/11795514241259741. View

Bourgonje A, Connelly M, Goor H, van Dijk P, Dullaart R . Both LDL and HDL particle concentrations associate positively with an increased risk of developing microvascular complications in patients with type 2 diabetes: lost protection by HDL (Zodiac-63). Cardiovasc Diabetol. 2023; 22(1):169. PMC: 10327395. DOI: 10.1186/s12933-023-01909-1. View

10.

Ahmad M, Shapiro M . Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome. Curr Atheroscler Rep. 2021; 23(4):16. DOI: 10.1007/s11883-021-00913-8. View

11.

Taylor R . Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013; 36(4):1047-55. PMC: 3609491. DOI: 10.2337/dc12-1805. View

12.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

13.

Elafros M, Andersen H, Bennett D, Savelieff M, Viswanathan V, Callaghan B . Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurol. 2022; 21(10):922-936. PMC: 10112836. DOI: 10.1016/S1474-4422(22)00188-0. View

14.

Zhu X, Deng F, Lei S . Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus. Prim Care Diabetes. 2014; 9(1):60-7. DOI: 10.1016/j.pcd.2014.03.007. View

15.

van Dijk C, Berl T . Pathogenesis of diabetic nephropathy. Rev Endocr Metab Disord. 2004; 5(3):237-48. DOI: 10.1023/B:REMD.0000032412.91984.ec. View

16.

Li Z, Huang Q, Sun L, Bao T, Dai Z . Atherogenic Index in Type 2 Diabetes and Its Relationship with Chronic Microvascular Complications. Int J Endocrinol. 2019; 2018:1765835. PMC: 6304911. DOI: 10.1155/2018/1765835. View

17.

Fernandez-Macias J, Ochoa-Martinez A, Varela-Silva J, Perez-Maldonado I . Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses. Arch Med Res. 2019; 50(5):285-294. DOI: 10.1016/j.arcmed.2019.08.009. View

18.

Zhang J, Liu C, Peng Y, Fang Q, Wei X, Zhang C . Impact of baseline and trajectory of the atherogenic index of plasma on incident diabetic kidney disease and retinopathy in participants with type 2 diabetes: a longitudinal cohort study. Lipids Health Dis. 2024; 23(1):11. PMC: 10782533. DOI: 10.1186/s12944-024-02003-5. View

19.

Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y . Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011; 96(11):3448-56. DOI: 10.1210/jc.2011-0622. View

20.

DeFronzo R, Ferrannini E, Groop L, Henry R, Herman W, Holst J . Type 2 diabetes mellitus. Nat Rev Dis Primers. 2016; 1:15019. DOI: 10.1038/nrdp.2015.19. View